Menu

Reconciliation of alternative performance measures


In CHF million
 


1.01.–30.09.2020
 


1.01.–30.09.2019
 

Change
reported
  Change
at constant
exchange
rates
                 
Net revenue                
Net revenue   8,201   8,456   –3.0%   –2.1%
                 
Operating income before depreciation and amortisation (EBITDA)                
EBITDA   3,356   3,360   –0.1%   0.7%
Adjustments lease expense     15      
EBITDA adjusted   3,356   3,375   –0.6%   0.2%
                 
Capital expenditure                
Capital expenditure in property, plant and equipment and intangible assets   1,621   1,791   –9.5%   –9.0%
Payments for indefeasible rights of use (IRU)   11   42   –73.8%    
Capital expenditure   1,632   1,833   –11.0%   –10.5%

In CHF million
 
1.01.–30.09.2020
 
1.01.–30.09.2019
  Change
reported
             
Operating free cash flow proxy            
Cash flow from operating activities   3,032   2,932   100
Capital expenditure   (1,632)   (1,833)   201
Depreciation of right-of-use assets   (217)   (205)   (12)
Depreciation of indefeasible rights of use (IRU)   18   23   (5)
Impairment losses of right-of-use assets   7     7
Change in deferred gain from the sale and leaseback of real estate   9   9  
Change in operating assets and liabilities   26   38   (12)
Change in provisions   27   5   22
Change in defined benefit obligations   (46)   (42)   (4)
Gain on sale of property, plant and equipment   8   12   (4)
Expense for share-based payments   (1)   (1)  
Revenue from finance leases   49     49
Interest received   (23)   (24)   1
Interest payments on financial liabilities   82   78   4
Dividends received   (15)   (18)   3
Income taxes paid   174   347   (173)
Operating free cash flow proxy   1,498   1,321   177
     
             
Free cash flow            
Cash flow from operating activities   3,032   2,932   100
Cash flow used in investing activities   (1,706)   (2,190)   484
Repayment of lease liabilities   (207)   (228)   21
Acquisition of subsidiaries, net of cash and cash equivalents acquired   30   385   (355)
Sale of subsidiaries, net of cash and cash equivalents sold     (1)   1
Expenses for shareholdings accounted for using the equity method   15   13   2
Purchase of other financial assets   122   53   69
Proceeds from other financial assets   (19)   (66)   47
Free cash flow   1,267   898   369